dpp 4 inhibitor and glp 1 agonist Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1 Effect of DPP4 inhibition on

[DOI] [PubMed] [Google Scholar] 59.Zhang J., An H., Ni K., Chen B., Li H., Li Y., Sheng G., Zhou C., Xie M., Chen S., et al

RSL3 inhibits the activity of GPX4, leading to a reduction in cellular antioxidant capacity and ROS accumulation, and ultimately to ferroptotic cell death (Yang et al., 2014)

Key takeaways Some individuals using Wegovy may develop an altered sense of taste, often described as metallic or unpleasant, though this side effect was not commonly reported in clinical trials

Values reported as the log risk ratio (logRR) between antioxidant and placebo groups

Li D, Hong X, Zhao F, Ci X, Zhang S

Some research suggests combining both agents may provide synergistic benefits, though this requires careful formulation (pH, stability considerations)